ReviewFuture science OA2025
Systematic review of scapular Ewing's sarcoma and a rare case of massive pleural effusion as primary manifestation.
Review in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEwing Sarcoma (ES) ranks second among mesenchymal malignancies in children and young adults. Scapular Ewing sarcoma (SES) represents <4% of ES cases with limited literature. We report a case of SES with uncommon respiratory symptoms in a 37-year-old male and conduct a systematic review to improve comprehension of SES demographics, clinical attributes, and management. LITERATURE REVIEW: A systematic search was conducted in PubMed, Scopus, and Google Scholar including SES case reports and series from 1983 to 2024. Using Covidence, references were screened. Two reviewers independently assessed eligibility, resulting in the inclusion of 32 studies. Risk of bias was assessed using Joanna Briggs Institute (JBI) checklists. A total of 124 SES cases were analyzed. SES predominantly affected adolescents with median age of 16 years; IQR: 12-24, and most commonly presented with shoulder swelling. A case within this cohort exhibited respiratory symptoms. Metastases occurred in 30% of cases, mainly to the lungs and bones. Remission was achieved in 64% of cases, while 29.7% had fatal outcomes.
conclusionThis review highlights the predominance of shoulder symptoms and identifies a unique respiratory presentation. Given the high metastatic rate, standardized protocols are needed to ensure oncological control and preserve shoulder function. REGISTRATION: PROSPERO,CRD420251008692.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.